How do I find a partner for clinical manufacturing?
Quotient is your answer.
We offer you manufacturing and testing services for all major dosage forms including:
- Solutions and suspensions
- Drug in bottle, drug in capsule
- Immediate, sustained and modified release tablets
- Solubilized formulations including amorphous (spray-dried and HME) dispersions, micronized and lipidic formulations
Routes of delivery
We have extensive experience developing and manufacturing drug products intended for all major routes of delivery:
- Oral (solid and liquid forms)
- Inhaled (pulmonary, nasal)
High-potency API handling
Take advantage of our state-of-the-art containment manufacturing for handling high-potency products which features isolator technology and engineered controls. Our containment classification is based on the Performance-Based-Level of Exposure Classification (PBLEC) allowing us to handle levels 1 through to 5 (or down to 0.1 µg/cubic meter) dependent upon the type of compound, dosage form and batch size.
Phase I and Phase II clinical trial manufacturing
Quotient can support all aspects of your drug product supply to support your Phase I, II and Phase III clinical studies:
- Manufacture of all major drug product dosage forms in our FDA and MHRA approved facilities
- Packaging including bottles, blisters, tubs or tubes
- Multi-language label design (including translation)
- Post-study drug return and reconcilliation
- Randomization and blinding
- Schedule I - IV controlled substance handling
- Shipment logistics and supply tracking
- Storage and distribution capabilities (ambient, refrigerated and frozen)
- Supply chain management to your clinical site
Real-time adaptive manufacturing
Our history and expertise of integrating manufacturing with clinical dosing enables us to manufacture, package and release products in a matter of days or weeks rather than months. Our approach maximizes flexibility around batch size and the timing of supply to your selected site, in response to emerging clinical data, or patient recruitment - all without affecting the availability of your drug product. Our approach can be used across all drug product types.
Global supply management
Quotient Sciences has reached a clinical trial supply milestone, providing over 2,000 drug products to over 60 unique clinical sites in hospitals and contract research organizations worldwide. We have a strong track record of on-time delivery of clinical supplies supporting your Phase I and II clinical studies, managing the packaging, multi-language labeling and door-to-door logistics in accordance with your clinical design. Our clinical trial supply team works with you to design the most efficient process for drug product supply to your central hub or clinical sites including the provision of bulk drug product or individual patient kits.
Clinical Trial Manufacturing
Understanding that early phase clinical testing is a pivotal milestone in the development of your drug product, Quotient Sciences offers clinical trial manufacturing, testing and certification services designed to meet your individual requirements.
Druggability Technologies (DRGT) is developing DRGT-46 as a novel therapy for pain. Gabor Heltovics, CEO of DRGT, explains how Quotient Sciences enabled the rapid development, clinical assessment and commercial readiness of its DRGT- 46 product using integrated services across Quotient’s network of harmonized development and manufacturing sites in the UK and US.
Rapid Development and Clinical Assessment of New Rectal and Oral Formulations for Ulcerative Colitis Using Real-Time Adaptive GMP Manufacturing and Supply
TOP1288 is a non-systemic kinase inhibitor (NSKI) being developed as a treatment for patients with ulcerative colitis. As a novel, locally-acting candidate, TOP1288 has low systemic bioavailability and therefore a dual-pronged formulation strategy was adopted with rectal and oral formulations being developed.
Pediatric Drug Development: Unique Considerations and Challenges
This webinar will explore product considerations when designing pediatric pharmaceutical products, clinical and operational considerations when executing and designing clinical trials for pediatric patient populations and regulatory considerations for pediatric drug development including US and EMEA incentives, guidance and requirements.